Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

New advanced PET approach helps surgeons stop epileptic seizures

University of Virginia School of Medicine researchers reported positive results after using their imaging technique in a small pilot study.

Humana

Humana agrees to take second look at panned payment change labeling PET/CT as ‘investigational’

The American Society of Nuclear Cardiology recently met with the Louisville, Kentucky, insurer, which shared an openness to reviewing a recent coverage determination. 

M&A mergers and acquisitions business deal

Medical imaging isotope producer Shine finalizes merger with fusion technology specialist

With the help of Phoenix's advanced industrial imaging capabilities, the new entity hopes to ramp up its production of molybdenum-99.

Thumbnail

Two new molecular imaging and therapy trials are underway

Hoag Family Cancer Institute in California is testing a radiotracer for myeloma and PSMA therapy in patients with high-risk prostate cancer.

ACR awards cancer institute national accreditation to perform PET/CT imaging

Patients visiting Quincy Medical Group will no longer have to undergo such exams on a mobile truck unit.

Thumbnail

New imaging agent for chronic diseases earns praise following first in-human trial

The PET radiotracer targets inflammation and quickly clears from the bloodstream, nuclear medicine experts reported in a new study.

Thumbnail

New PET agent may ‘revolutionize’ diagnostic workup for numerous diseases

Molecular Targeting Technologies, a privately owned biotech company, recently won a patent for its 18F-fluroglucaric acid necrosis agent.

Thumbnail

Amid COVID-19 vaccine rollout, providers may slowly resume ventilation/perfusion lung scans

SNMMI said V/Q scans can be increasingly incorporated as a normal part of the workup of suspected pulmonary embolism.